From: Is pathology necessary to predict mortality among men with prostate-cancer?
 | HR 95% CI | p | |
---|---|---|---|
Age | 1.1 (1.093-1.15) | <0.0001 | |
Year of cohort entry | 0.95 (0.93-0.96) | <0.0001 | |
Rural | 1.29 (1.13-1.48) | 0.0002 | |
Co morbidity ADGs | Low | ref | Â |
Intermediate | 1.31 (1.15-1.51) | <0.0001 | |
High | 1.65 (1.45-1.89) | <0.0001 | |
SES status | 1 | ref | Â |
2 | 0.94 (0.81-1.1) | 0.43 | |
3 | 0.99 (0.85-1.17) | 0.93 | |
4 | 0.78 (0.66-0.92) | 0.004 | |
5 | 0.85 (0.72-0.99) | 0.05 | |
Gleason grade | Low | ref | Â |
Intermediate | 1.16 (1.01-1.3) | 0.04 | |
High | 2.3 (1.97-2.64) | <0.0001 | |
Volume of prostate cancer | Low (≤30%) | ref |  |
High ( >30%) | 1.14 (1.01-1.29) | 0.036 |